UNSPSC 51332815: Mesoridazine

This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26N2OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XE4NWM740, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)- but generally known as mesoridazine, which bears US NIH Compound Identifier 4078. European Medicines Agency schedules Mesoridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08786MIG.

UNSPSC 51332815 Mesoridazine is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies and multistate cooperative purchasing groups — though recent solicitations under this code tag show limited activity directly matching the mesoridazine antipsychotic drug itself. The recent opportunities posted under this code reflect a broader pharmaceutical and opioid-response procurement landscape: Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB; Texas HHS issued an RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products. Issuing bodies range from county health departments to state health agencies and multistate cooperative purchasing vehicles, with MMCAP serving Oregon and Minnesota state and local government facilities alongside its home state.

Recent activity concentrates in the Upper Midwest and South. The MMCAP RFP posted January 20, 2026 (response deadline March 26, 2026) covers Minnesota and Oregon and requires vendors to supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with contract effectiveness July 1, 2026 and evaluation weighted heavily (75 percent) on price competitiveness. Seminole County's IFB 60459723LAS, posted June 30, 2026 (due July 26, 2023, though the date appears inconsistent with the posting date), seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to 520 W. Lake Mary Blvd, Sanford, Florida. Texas HHS's RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) explores vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The code shows pharmaceutical procurement activity but limited direct solicitation of mesoridazine as a line item in recent state and local notices.